Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations

References

• VaquezHSur une forme speciale de cyanose s’accompanant d’hyperglobulie excessive et persistanteCR Soc Biol (Paris)18924384
   Google Scholar
• OslerWChronic cyanosis with polycythemia and enlarged spleen: a new clinical entity. 1930Am J Med Sci2008335641141718552568
   PubMed Web of Science ®Google Scholar
• TamCSNussenzveigRMPopatUThe natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasmsBlood200811251628163718566326
   PubMed Web of Science ®Google Scholar
• TefferiAAnnual clinical updates in hematological malignancies: a continuing medical education series: polycythemia vera en essential thrombosis: 2011 update on diagnosis, risk-stratification, and managementAm J Hematol201186329230121351120
   PubMed Web of Science ®Google Scholar
• TefferiAVardimanJWClassification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithmsLeukemia2008221142217882280
   PubMed Web of Science ®Google Scholar
• DameshekWSome speculations on the myeloproliferative syndromesBlood19516437237514820991
   PubMed Web of Science ®Google Scholar
• PrchalJFAxelradAALetter: bone-marrow responses in polycythemia veraN Engl J Med19742902413824827655
   PubMed Web of Science ®Google Scholar
• CasadevallNVainchenkerWLacombeCErythroid progenitors in polycythemia vera: demonstration of their hypersensitivity to erythropoietin using serum free culturesBlood19825924474517055650
   PubMed Web of Science ®Google Scholar
• CashmanJHenkelmanDHumphriesKEavesCEavesAIndividual BFU-E in polycythemia vera produce both erythropoietin dependent and independent progenyBlood19836158768846831048
   PubMed Web of Science ®Google Scholar
• JamesCUgoVLe CouedicJPA unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature200543470371144114815793561
   PubMed Web of Science ®Google Scholar
• BaxterEJScottLMCampbellPJCancer Genome ProjectAcquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersLancet200536594641054106115781101
   PubMed Web of Science ®Google Scholar
• KralovicsRPassamontiFBuserASA gain-of-function mutation of JAK2 in myeloproliferative disordersN Engl J Med2005352171779179015858187
   PubMed Web of Science ®Google Scholar
• LevineRLWadleighMCoolsJActivating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisCancer Cell20057438739715837627
   PubMed Web of Science ®Google Scholar
• Quintás-CardamaAVaddiKLiuPPreclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasmsBlood2010115153109311720130243
   PubMed Web of Science ®Google Scholar
• VerstovsekSPassamontiFRambaldiAA phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyureaCancer2014120451352024258498
   PubMed Web of Science ®Google Scholar
• VannucchiAMKiladjianJJGriesshammerMRuxolitinib versus standard therapy for the treatment of polycythemia veraN Engl J Med2015372542643525629741
   PubMed Web of Science ®Google Scholar
• TheocharidesABoissinotMGirodonFLeukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutationBlood2007110137537917363731
   PubMed Web of Science ®Google Scholar
• MehtaJWangHIqbalSUMesaREpidemiology of myeloproliferative neoplasms in the United StatesLeuk Lymphoma201455359560023768070
   PubMed Web of Science ®Google Scholar
• PhekooKJRichardsMAMollerHScheySASouth Thames Haematology Specialist CommitteeThe incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast EnglandHaematologica200691101400140417018393
   PubMed Web of Science ®Google Scholar
• SkodaRPrchalJTLessons from familial myeloproliferative disordersSemin Hematol200542426627316210040
   PubMed Web of Science ®Google Scholar
• SalibaJSaint-MartinCDi StefanoAGermline duplication of ATG2B and GSKIP predisposes to familial myeloid malignanciesNat Genet201547101131114026280900
   PubMed Web of Science ®Google Scholar
• TefferiARumiEFinazziGSurvival and prognosis among 1545 patients with contemporary polycythemia vera: an international studyLeukemia20132791874188123739289
   PubMed Web of Science ®Google Scholar
• BarbuiTBarosiGBirgegardGPhiladelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European Leukemia NetJ Clin Oncol201129676177021205761
   PubMed Web of Science ®Google Scholar
• McMullinMFWilkinsBSHarrisonCNManagement of polycythaemia vera: a critical review of current dataBr J Haematol2016172333734926492433
   PubMed Web of Science ®Google Scholar
• EmanuelRMDueckACGeyerHLMyeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNsJ Clin Oncol201230334098410323071245
   PubMed Web of Science ®Google Scholar
• TefferiAElliottMThrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617FSemin Thromb Hemost200733431332017525888
   PubMed Web of Science ®Google Scholar
• MarchioliRFinazziGSpecchiaGCardiovascular events and intensity of treatment in polycythemia veraN Engl J Med20133681223323216616
   PubMed Web of Science ®Google Scholar
• Quintas-CardamaAKantarjianHManshouriTPegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia veraJ Clin Oncol200927325418542419826111
   PubMed Web of Science ®Google Scholar
• KremyanskayaMMascarenhasJHoffmanRAnagrelide hydrochloride and ruxolitinib for treatment of polycythemia veraExpert Opin Pharmacother20151681185119425873215
   PubMed Web of Science ®Google Scholar
• CortelazzoSFinazziGRuggeriMHydroxyurea for patients with essential thrombocythemia and a high risk of thrombosisN Engl J Med199533217113211367700286
   PubMed Web of Science ®Google Scholar
• BerkPDGoldbergJDDonovanPBFruchtmanSMBerlinNIWassermanLRTherapeutic recommendations in polycythemia vera based on polycythemia vera study group protocolsSemin Hematol19862321321433704665
   PubMed Web of Science ®Google Scholar
• LandolfiRMarchioliREuropean collaboration on low-dose aspirin in polycythemia vera (ECLAP): a randomized trialSemin Thromb Hemost19972354734789387206
   PubMed Web of Science ®Google Scholar
• LandolfiRMarchioliRKuttiJEfficacy and safety of low-dose aspirin in polycythemia veraN Engl J Med2004350211412414711910
   PubMed Web of Science ®Google Scholar
• ArberDAOraziAHasserjianRThe 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemiaBlood2016127202391240527069254
   PubMed Web of Science ®Google Scholar
• DaiCHKrantzSBDessyprisENMeansRTJrHornSTGilbertHSPolycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factorBlood19928048918991498332
   PubMed Web of Science ®Google Scholar
• de WolfJTHendriksDWEsselinkMTHalieMRVellengaEThe effects of IL-1 and IL-4 on the EPO-independent erythroid progenitor in polycythaemia veraBr J Haematol19948822422467803266
   PubMed Web of Science ®Google Scholar
• MarchioliRVannucchiAMBarbuiTTreatment target in polycythemia veraN Engl J Med201336816155623594012
   PubMedGoogle Scholar
• LacoutCPisaniDFTulliezMGachelinFMVainchenkerWVillevalJLJAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosisBlood200610851652166016670266
   PubMed Web of Science ®Google Scholar
• LundbergPTakizawaHKubovcakovaLMyeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617FJ Exp Med2014211112213223025288396
   PubMed Web of Science ®Google Scholar
• NussenzveigRHSwierczekSIJelinekJPolycythemia vera is not initiated by JAK2V617F mutationExp Hematol2007351323817198871
   PubMed Web of Science ®Google Scholar
• ScottLMScottMACampbellPJGreenARProgenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemiaBlood200610872435243716772604
   PubMed Web of Science ®Google Scholar
• YanDHutchisonREMohiGCritical requirement for Stat5 in a mouse model of polycythemia veraBlood2012119153539354922144185
   PubMed Web of Science ®Google Scholar
• WalzCAhmedWLazaridesKEssential role for Stat5a/b in myeloproliferative neoplasms induced by BCRABL1 and JAK2V617F in miceBlood2012119153550356022234689
   PubMed Web of Science ®Google Scholar
• ScottLMTongWLevineRLJAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosisN Engl J Med2007356545946817267906
   PubMed Web of Science ®Google Scholar
• IshiiTBrunoEHoffmanRXuMInvolvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia veraBlood200610893128313416757685
   PubMed Web of Science ®Google Scholar
• SozerSFielMISchianoTXuMMascarenhasJHoffmanRThe presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndromeBlood2009113215246524919293426
   PubMed Web of Science ®Google Scholar
• WernigGKharasMGOkabeREfficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia veraCancer Cell200813431132018394554
   PubMed Web of Science ®Google Scholar
• MascarenhasJOCrossNCMesaRAThe future of JAK inhibition in myelofibrosis and beyondBlood Rev201428518919625043171
   PubMed Web of Science ®Google Scholar
• AlchalbyHKrogerNAllogeneic stem cell transplant vs. Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia veraClin Lymphoma Myeloma Leuk201414supplS36S4125486953
   PubMed Web of Science ®Google Scholar
• SwaimSJRuxolitinib for the treatment of primary myelofibrosisAm J Health Syst Pharm201471645346224589536
   PubMed Web of Science ®Google Scholar
• ChenXWilliamsWVSandorVYeleswaramSPopulation pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF)J Clin Pharmacol201353772173023677817
   PubMed Web of Science ®Google Scholar
• ShillingADNedzaFMEmmTMetabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humansDrug Metab Dispos201038112023203120699411
   PubMed Web of Science ®Google Scholar
• ChenXShiJGEmmTPharmacokinetics and pharmacodynamics of orally-administered ruxolitinib (INCB 0184 24 phosphate) in renal and hepatic impairment patientsClin Pharmacol Drug Dev201431344227128228
   PubMed Web of Science ®Google Scholar
• CervantesFVannucchiAMKiladjianJJThree-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosisBlood2013122254047405324174625
   PubMed Web of Science ®Google Scholar
• VerstovsekSKantarjianHMesaRASafety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosisN Engl J Med2010363121117112720843246
   PubMed Web of Science ®Google Scholar
• MesaRVannucchiAMYacoubAThe efficacy and safety of continued hydroxyurea therapy versus switching to ruxolitinib in patients with polycythemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)Blood2014124213168
   Web of Science ®Google Scholar
• VerstovsekSMesaRAGotlibJEfficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-IHaematologica2015100447948825616577
   PubMed Web of Science ®Google Scholar
• VannucchiAMKantarjianHMKiladjianJJA pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosisHaematologica201510091139114526069290
   PubMed Web of Science ®Google Scholar
• PassamontiFRumiEPungolinoELife expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemiaAm J Med20041171075576115541325
   PubMed Web of Science ®Google Scholar
• ShiraneSArakiMMorishitaSConsequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemiaInt J Hematol2015101214815325522845
   PubMed Web of Science ®Google Scholar
• TiedtRHao-ShenHSobasMARatio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic miceBlood200811183931394018160670
   PubMed Web of Science ®Google Scholar
• KiladjianJJCassinatBChevretSPegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia veraBlood200811283065307218650451
   PubMed Web of Science ®Google Scholar
• PassegueEErnstPIFN-alpha wakes up sleeping hematopoietic stem cellsNat Med200915661261319498372
   PubMed Web of Science ®Google Scholar
• PrchalJFInterferon and PV stem cellsInside Blood2011118614291430
   Web of Science ®Google Scholar
• KingKYBaldridgeMTWeksbergDCIrgm1 protects hematopoietic stem cells by negative regulation of interferon signalingBlood201111861525153321633090
   PubMed Web of Science ®Google Scholar
• BjørnMEde StrickerKKjærLEllemannKHasselbalchHCCombination therapy with interferon and JAK1-2 inhibitor is feasible: proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia veraLeuk Res Rep201432737525379406
   PubMedGoogle Scholar
• SzymanskaJSmolewskiPMajchrzakACebula-ObrzutBChojnowskiKTrelinskiJPro-apoptotic activity of ruxolitinib alone and in combination with hydroxyurea, busulphan, and PI3K/mTOR inhibitors in JAK2-positive human cell linesAdv Clin Exp Med201524219520225931349
   PubMed Web of Science ®Google Scholar
• MartyCLacoutCDroinNA role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progressionLeukemia201327112187219523558526
   PubMed Web of Science ®Google Scholar
• HasselbalchHCPerspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?Blood2012119143219322522318201
   PubMed Web of Science ®Google Scholar
• Mendez-FerrerSMichurinaTVFerraroFMesenchymal and haematopoietic stem cells form a unique bone marrow nicheNature2010466730882983420703299
   PubMed Web of Science ®Google Scholar
• PardananiAHarrisonCNCortesJEResults of a randomized, double-blind, placebo-controlled phase III study (JAKARTA) of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (MF)Blood201312221393
   Web of Science ®Google Scholar
• PardananiALabordeRRLashoTLSafety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosisLeukemia20132761322132723459451
   PubMed Web of Science ®Google Scholar
• PardananiAHarrisonCCortesJESafety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trialJAMA Oncol20151564365126181658
   PubMed Web of Science ®Google Scholar
• VerstovsekSDeanJPCernohousPPacritinib, a dual JAK2/FLT3 inhibitor: an integrated efficacy and safety analysis of phase ii trial data in patients with primary and secondary myelofibrosis (MF) and platelet counts ≤100,000/μlBlood201312221395
   Web of Science ®Google Scholar
• MeyerSCKellerMDChiuSCHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasmsCancer Cell2015281152826175413
   PubMed Web of Science ®Google Scholar
• SamuelsonBTVeselySKChai-AdisaksophaCScottBLCrowtherMGarciaDThe impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysisBlood Coagul Fibrinolysis20162764865226569516
   PubMed Web of Science ®Google Scholar
• VerstovsekSMesaRAGotlibJA double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisN Engl J Med2012366979980722375971
   PubMed Web of Science ®Google Scholar